Cash Flow Statement (Annual)

BSFT / BroadSoft, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Supplemental Cash Flow Information
  Income Taxes Paid 1,977 1,261 385 1,363 422 1,678 2,377 3,572
  Interest Paid Net 1,451 655 1,032 905 1,895 1,801 1,418 3,000
  Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 - - - 1,800 528 688 2,153 1,523
Net Cash Provided By Used In Investing Activities
  Increase Decrease In Restricted Cash -708 -29 -14 -375 -3 -564 0 -
  Finite Lived Intangible Assets Purchase Accounting Adjustments - -809 -905 0 0 - - -
  Proceeds From Sale Of Available For Sale Securities - - 11,267 3,000 0 10,000 128,827 106,355
  Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities - - 46,962 171,458 103,240 109,042 69,677 69,085
  Payments To Acquire Marketable Securities - 18,673 137,305 179,886 117,067 122,991 252,467 281,111
  Payments To Acquire Businesses Net Of Cash Acquired -806 2,191 16,748 25,177 37,793 3,650 21,172 34,678
  Net Cash Provided By Used In Investing Activities 694 -24,274 -99,136 -34,153 -57,406 -17,558 -88,011 -156,087
  Payments To Acquire Property Plant And Equipment 769 2,630 2,421 3,923 5,789 10,523 12,876 15,738
Net Cash Provided By Used In Financing Activities
  Proceeds From Warrant Exercises - 100 - - - - - -
  Proceeds From Issuance Of Common Stock - 9,932 - - - - - -
  Proceeds From Issuance Initial Public Offering - 39,951 - - - - - -
  Payments For Repurchase Of Preferred Stock And Preference Stock - 4,320 - - - - - -
  Repayments Of Long Term Debt 2,753 16,697 1,626 382 969 0 0 -
  Proceeds From Stock Options Exercised 69 762 3,943 2,459 1,285 710 6,187 15,181
  Net Cash Provided By Used In Financing Activities -2,684 29,203 117,431 -121 4,831 -4,135 118,918 -2,467
  Excess Tax Benefit From Share Based Compensation Financing Activities - - 61 579 7,492 2,950 1,809 296
  Taxes Paid On Vesting Of Rsus - 525 574 2,198 2,977 7,795 10,297 17,944
  Proceeds From Issuance Of Convertible Senior Notes Net Of Issuance Costs - - 115,688 0 0 - - -
  Payments For Repurchase Of Common Stock - - - - 0 0 25,002 0
  Proceeds From Issuance Of Senior Long Term Debt - - - - 0 0 194,822 0
  Repayments Of Senior Debt - - - - 0 0 48,601 0
Effect Of Exchange Rate On Cash And Cash Equivalents 79 70 -52 149 -38 -1,389 -1,379 -1,407
Cash And Cash Equivalents Period Increase Decrease 8,516 24,385 46,818 -3,527 -20,679 31,677 74,314 -92,864
Cash And Cash Equivalents At Carrying Value - - 94,072 90,545 69,866 101,543 175,857 82,993
Net Cash Provided By Used In Operating Activities
  Net Cash Provided By Used In Operating Activities 10,427 19,386 28,575 30,598 31,934 54,759 44,786 67,097
  Increase Decrease In Operating Capital
    Increase Decrease In Other Operating Assets 1,004 463 511 16,414 1,128 4,056 4,896 7,606
    Increase Decrease In Deferred Revenue 18,869 19,217 -3,240 4,013 16,473 22,911 9,099 -2,000
    Increase Decrease In Accounts Payable And Accrued Liabilities -3,532 630 238 -1,125 -1,799 4,655 2,234 4,815
    Increase Decrease In Accounts Receivable 4,147 15,023 5,997 2,557 16,334 14,806 23,935 12,499
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Valuation Allowance Deferred Tax Asset Change In Amount - - 8,946 0 0 - - -
    Tax Benefit From Stock Options Exercised1 - - 61 579 - - - -
    Change In Fair Value Of Preferred Stock Warrants And Accretion Of Debt Discount -137 -153 - - - - - -
    Other Noncash Income Expense -101 - -24 0 0 - - -
    Share Based Compensation 3,629 3,008 7,201 15,022 41,684 29,628 40,444 51,507
    Provision For Doubtful Accounts 59 3 -56 644 149 274 4 313
    Paid In Kind Interest - - 2,560 5,120 5,504 5,906 8,617 12,684
    Excess Tax Benefit From Share Based Compensation Operating Activities - - - 579 7,492 2,950 1,809 296
    Deferred Income Taxes And Tax Credits - 7 5 5,088 -7,058 -3,548 -2,741 -2,031
    Amortization Of Software Licenses 1,820 1,820 1,820 2,910 2,987 3,342 2,848 3,401
    Depreciation And Amortizations 2,209 2,348 3,119 5,242 7,822 12,391 15,836 17,993
    Payment Of Debt Discount - - - - 0 0 1,094 0
    Deferred Tax Expense From Stock Options Exercised - - -61 -579 -7,492 - - -
  Net Income Loss -7,849 7,992 32,297 12,076 -8,874 1,012 179 816

Peers - Prepackaged Software (7372)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 11133B409